- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Ethnicity and Socioeconomic Status Determine Breast Cancer Susceptibility
A study published in the journal Breast Cancer Research and Treatment identified increased incidence of triple negative breast cancer in black women compared to white women, while those with Asian heritage were found more susceptible to HER2-positive breast cancer.
An analysis of a large nationwide dataset finds that regardless of their socioeconomic status, black women were nearly twice as likely as white women to be diagnosed with triple-negative (TN) breast cancer, a subtype that has a poorer prognosis. The analysis also found that Asian/Pacific Islander women were more likely to be diagnosed with another subtype of breast cancer: so-called human epidermal growth factor receptor 2 (HER2)—overexpressing breast cancer. The study appears early online in Breast Cancer Research and Treatment.
Triple-negative breast cancers are those whose cells lack estrogen receptors and progesterone receptors, and do not have an excess of the HER2 protein on their surfaces. Triple-negative breast cancers tend to grow and spread more quickly than most other types of breast cancer
, and a lack of these receptors limits treatment options.
Read the report here:
Source: MedicalXpress
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Trastuzumab Deruxtecan Receives FDA Approval for HER2-Positive Solid Tumors
April 5th 2024FDA granted accelerated approval to trastuzumab deruxtecan-nxki for adult patients with unresectable or metastatic HER2-positive solid tumors who received prior systemic treatment and have no satisfactory alternative treatment options.
Read More
